Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ: MGNX )

2.200 -0.180 (-7.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
What 5 Analyst Ratings Have To Say About Macrogenics
  Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
MacroGenics Jumps Biotech Layoff Bandwagon, Cuts 15% Of Workforce
Via Benzinga
Analyst Ratings for Macrogenics
Over the past 3 months, 5 analysts have published their opinion on Macrogenics (NASDAQ:MGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
MacroGenics Shares Jump On Gilead Licensing Pact For Blood Cancer Candidates
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 46.1% to $0.49 during Monday's pre-market session. The company's market cap stands at $11.9 million. 
Via Benzinga
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
From Gilead Sciences, Inc.
Via Business Wire
Macrogenics: Q2 Earnings Insights
  Macrogenics (NASDAQ:MGNX) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Analysts Cuts Price Target On MacroGenics - Read Why
Via Benzinga
Analyst Ratings for Macrogenics
Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study
Via Benzinga
This Analyst Slashes PT On Meta Platforms, Plus Mizuho Predicts $440 For Adobe
Mizuho cut the price target for Adobe Inc (NASDAQ: ADBE) from $480 to $440. Adobe shares fell 1.3% to $389.82 in pre-market trading. 
Via Benzinga
Where Macrogenics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Macrogenics (NASDAQ:MGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers
Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading. 
Via Benzinga
Earnings Preview: Macrogenics
Macrogenics (NASDAQ:MGNX) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Macrogenics will... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million. 
Via Benzinga
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,... 
Via Benzinga
Why Is F45 Training Holdings Down By 56%? Here Are 28 Stocks Moving In Wednesday's Pre-Market Session
Gainers Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday
Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Sana Biotechnology (NASDAQ:SANA) shares moved upwards by 9.1% to $6.1 during Friday's after-market session. The company's market cap stands at $1.1 billion. 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.